Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
G Bogani, B J Monk, M A Powell, et al.
The Canadian Journal of Urology
|
February 28, 2007
Research priorities for urological care following spinal cord injury: recommendations of an expert panel
K C Hayes, K Bassett-Spiers, R Das, et al.
Gynecologic Oncology
|
August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
K N Slaughter Wade, M F Brady, T Thai, et al.
Gynecologic Oncology
|
January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
L R Duska, C N Krasner, D M O'Malley, et al.
Gynecologic Oncology
|
May 1, 2022
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium
C G Jackson, K N Moore, L Cantrell, et al.
Gynecologic Oncology
|
November 6, 2025
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
C Washington, Shailendra Kumar Dhar Dwivedi, C Gunderson-Jackson, et al.
Gynecologic Oncology
|
June 14, 2023
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
B Pothuri, S V Blank, T K Myers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
G Bogani, B J Monk, M A Powell, et al.
The Canadian Journal of Urology
|
February 28, 2007
Research priorities for urological care following spinal cord injury: recommendations of an expert panel
K C Hayes, K Bassett-Spiers, R Das, et al.
Gynecologic Oncology
|
August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
K N Slaughter Wade, M F Brady, T Thai, et al.
Gynecologic Oncology
|
January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
L R Duska, C N Krasner, D M O'Malley, et al.
Gynecologic Oncology
|
May 1, 2022
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium
C G Jackson, K N Moore, L Cantrell, et al.
Gynecologic Oncology
|
November 6, 2025
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
C Washington, Shailendra Kumar Dhar Dwivedi, C Gunderson-Jackson, et al.
Gynecologic Oncology
|
June 14, 2023
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
B Pothuri, S V Blank, T K Myers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Page
of 7